Updated:
Joinn Laboratories (China)
Joinn Laboratories (China) is a corporate investor based in Beijing, China. It manages $1.4 billion in assets across two funds, primarily focused on Asia.
Joinn Laboratories (China)
Joinn Laboratories (China) is a corporate investor based in Beijing, China. It manages $1.4 billion in assets across two funds, primarily focused on Asia.
General information
Firm type
Corporate Investor
Year founded
1995
Location
Region
Asia
Country
China
City
Beijing
Corporate office
No. 5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, China
Additional offices
Suzhou, Jiangsu Province, China · Northern California, USA · Wuzhou, Guangxi, China
Principals
Feng Yuxia
Chairperson
Zhou Zhiwen
Co-founder
Sector focus
Frequently asked questions
Who controls Joinn Laboratories?
Feng Yuxia co-founded the firm in 1995 and remains chairperson and controlling shareholder. Her spouse Zhou Zhiwen is also a co-founder. The founders' son, Zhou Fengyuan, owns Biorichland, a related-party real estate entity that leases facilities back to Joinn.
What makes Joinn's investment model structurally different from other CROs?
Joinn owns and operates captive non-human primate breeding colonies across multiple sites in southern China. During periods of global NHP supply tightness, this gives Joinn a cost and availability advantage in preclinical studies and allows the firm to invest directly in drug-development programs while underwriting the service revenue.
Does Joinn Laboratories invest directly in biotech companies?
Yes. Joinn acts as a corporate investor that takes direct equity stakes in early-stage biotech and pharmaceutical programs, often alongside its preclinical service agreements. The firm has publicly documented a co-investment relationship with Nexelis for bioanalytical studies servicing clinical trials in China.
Where does Joinn derive its biologic assets?
Joinn maintains dedicated non-human primate breeding bases in Wuzhou (Guangxi Zhuang Autonomous Region), Yunnan, and Nanning. These captive colonies supply the firm's preclinical toxicology and pharmacology operations and function as a strategic asset held on its balance sheet.
Does Joinn maintain operations outside of China?
The firm owns a commercial research property in Northern California, which extends its preclinical toxicology capabilities internationally and offers a regulatory foothold for clients pursuing FDA submissions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: